Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma

This study found that a biomarker called Fractional exhaled nitric oxide (FeNO) could predict how patients with uncontrolled, moderate-to-severe asthma would benefit from the asthma drug, dupilumab. This is important because it identifies which asthma patients would benefit from this drug, which improves the efficiency of these treatments. Coauthor Thomas Casale, MD is an ACRC Investigator.
Asthma Basics Workshop - National
, | Apr 17, 2024
Asthma Basics Workshop - National
, | May 07, 2024